CN104042925A - Traditional Chinese medicinal composition for treating gout and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN104042925A CN104042925A CN201410327286.4A CN201410327286A CN104042925A CN 104042925 A CN104042925 A CN 104042925A CN 201410327286 A CN201410327286 A CN 201410327286A CN 104042925 A CN104042925 A CN 104042925A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 201000005569 Gout Diseases 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims description 33
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 241000903946 Clematidis Species 0.000 claims abstract description 11
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 5
- 241000241550 Cyathula Species 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 120
- 229940079593 drug Drugs 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 241000180649 Panax notoginseng Species 0.000 claims description 7
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- 241001250596 Pleione Species 0.000 claims description 5
- 241000545442 Radix Species 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 241000245240 Lonicera Species 0.000 claims description 2
- 241000612166 Lysimachia Species 0.000 claims description 2
- 241001522129 Pinellia Species 0.000 claims description 2
- 241000208966 Polygala Species 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 44
- 241001571764 Lysimachia christinae Species 0.000 abstract description 3
- 241001522232 Pinellia ternata Species 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 abstract description 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 240000002234 Allium sativum Species 0.000 abstract 1
- 241000031023 Amana edulis Species 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000189799 Asimina triloba Species 0.000 abstract 1
- 235000006264 Asimina triloba Nutrition 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 235000009467 Carica papaya Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000004611 garlic Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 208000002193 Pain Diseases 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 230000036407 pain Effects 0.000 description 21
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 17
- 241000700159 Rattus Species 0.000 description 13
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 13
- 229940116269 uric acid Drugs 0.000 description 13
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 9
- 206010014025 Ear swelling Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 206010018634 Gouty Arthritis Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- KUKRLSJNTMLPPK-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2(C)C=CC1C2(C)C KUKRLSJNTMLPPK-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 241001671653 Aconitum carmichaelii Species 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 241000756998 Alismatales Species 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- GLVKGYRREXOCIB-UHFFFAOYSA-N Bornylene Natural products CC1CCC(C(C)(C)C)C=C1 GLVKGYRREXOCIB-UHFFFAOYSA-N 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000601157 Clematis angustifolia Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000735234 Ligustrum Species 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000304447 Sempervivum tectorum Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001366 anti-paroxysmal effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicinal composition for treating gout and relates to the technical field of traditional Chinese medicines. The composition comprises the following components in parts by weight: 10-50 parts of edible tulip, 5-15 parts of astragalus membranaceus, 10-20 parts of notopterygium root, 5-20 parts of Chinese angelica, 5-10 parts of raw rehmmania, 5-15 parts of lysimachia christinae hance, 5-15 parts of honeysuckle, 3-10 parts of radix clematidis, 3-8 parts of monkshood, 5-15 parts of medlar, 9-15 parts of medicinal cyathula root, 3-5 parts of pinellia ternata, 5-10 parts of pawpaw, 3-5 parts of radix paeoniae alba, 5-10 parts of pseudo-ginseng, 9-15 parts of ligusticum wallichii, 5-15 parts of angelica root, 5-10 parts of jujube kernel, 5-15 parts of poria, 3-9 parts of kudzuvine root, 5-15 parts of garlic, 6-9 parts of glossy privet fruit and 10-15 parts of liquorice. The traditional Chinese medicinal composition has a good effect on the aspect of treatment or prevention of gout, hardly causes side effects, and has a remarkable clinical popularization value.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Chinese medicine composition for the treatment of gout and preparation method thereof.
Background technology
Gout is due to purine metabolic disturbance and underexcretion, and hyperuricemia, acute arthritis are shown effect repeatedly, tophus formation, chronic arthritis and joint deformity, and occur urate calculus and gouty parenchymal lesion of the kidney in the course of disease later stage.Its sickness rate increases year by year, becomes the second largest metabolic disease of the mankind after diabetes.
Gouty arthritis (goutyarthritis, GA) is to be increased by serum Uric Acid Concentration due to purine metabolism obstacle, thereby urate crystal is deposited on a kind of metabolic osteoarthritis that joint causes.Uric acid sodium (monsodiumurate, MSU) crystal is proved to be the non-microorganism sexually transmitted disease (STD) substance of GA, and the immune inflammation of its induction plays an important role in the morbidity of GA.
Acute GA outbreak is mainly by synovial membrane inflammatory cell infiltration, uric acid deposition, tissue local necrosis, early stage urate crystal comes off and enters in synovial fluid from calm synovial membrane, protein in synovial fluid is adsorbed in crystal surface immediately, and engulfed by synovial cell, multinuclear leucocyte, monocyte, macrophage, synovial membrane surface congestion and edema, due to cell infiltration.
Therapeutically, the pathophysiological mechanism that antigout drug occurs mainly for gout, can by suppress uric acid synthetic, promote urate excretion or inflammation-inhibiting reaction to bring into play gout effect.The treatment of gout acute attack mainly adopts non-salicylic acid NSAID (non-steroidal anti-inflammatory drug) and colchicine, and the primary treatment object of chronic gout is to reduce uric acid content in blood, conventional probenecid and allopurinol etc.Yet these medicines are all because curative effect is limited, untoward reaction is limited compared with large clinical practice.
Be mainly single chemicals and preparations thereof of research and development the eighties in the past, starts to develop biotechnology and natural medicinal plants after the eighties, and drug research direction is tending towards multiformity.In conjunction with modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened to the preparation that extraction and/or compatibility make, its side effect is little, safe, has the advantage that chemical synthetic drug can not be compared.
As, CN1899481A discloses a kind of gout plaster for the treatment of gout, carbuncle furuncle poison, and it is made by the crude drug of following corresponding weight number, Radix et Rhizoma Dysosmatis 8-12g, Rhizoma Dioscoreae 8-12g, Rhizoma Paridis 4-6g, Fu Ling 8-12, Radix Trichosanthis 8-12g.By the weight ratio of crude drug, take each component, by each component pulverization, with Mel, mix well external.This ointment can play detumescence effect of ejecting poison.CN1895522A discloses a kind of gout granules, by raw materials such as Rhizoma Smilacis Glabrae, Bombyx mori L., Radix Clematidis, Rhizoma Dioscoreae Hypoglaucae, Rhizoma Paridis, Radix Cynanchi Paniculati, Semen Plantaginiss, is made.CN103330926A discloses a kind of toxin expelling gout spirit, comprises following composition: Ramulus Cinnamomi 15-30 weight portion, Radix Paeoniae Alba 20-40 weight portion, Rhizoma Zingiberis Recens 20-30 weight portion, Fructus Jujubae 10-20 weight portion, Radix Glycyrrhizae 15-30 weight portion, Radix Puerariae 20-40 weight portion, Cortex Magnoliae Officinalis 15-30 weight portion, Fructus Aurantii Immaturus 15-20 weight portion, Radix Et Rhizoma Rhei 10-30 weight portion, gets rid of bulky 20-30 weight portion, Rhizoma Smilacis Glabrae 30-60 weight portion, Radix Clematidis 20-30 weight portion.Toxin expelling gout spirit of the present invention, has synergism to gout, focuses on internal cleaning By inducing sweat, and obviously shorten the course for the treatment of.CN101062087A medicine capsule for treating gout for the treatment of gout, this medicine by following raw materials according by weight ratio form: Hirudo 40-60 part, Olibanum 10-20 part, Myrrha 10-20 part, Radix Notoginseng 4-8 part, Radix Gentianae Macrophyllae 5-10 part, Radix Stephaniae Tetrandrae 5-10 part, Borneolum Syntheticum 0.5-1.5 part.The present invention has positive effect to the treatment of goat, primary symptom muscular soreness, arthroncus, sharp ache unbearably or color of the leather dark red livid purple etc.
In addition, CN1931245A, CN101732623A, CN101249173A etc. have all announced medicine for the treatment of gouty arthritis separately and preparation method thereof.The medicine that these methods are made all has certain effect to relief of symptoms, but last curative effect all can not be satisfactory, is mainly speed and the disease radical cure aspect course for the treatment of, and a lot of patients can be recurred again soon.
The gentle mediation of Chinese prescription is a desirable scheme of dialectical treatment gout.But in prior art, the technical problem such as the onset of Treated with Chinese Decoction gout ubiquity is slow, and specific aim is not strong, and cure rate is low.
Summary of the invention
Large in order to overcome existing gout chemotherapeutic agent toxic and side effects, gout treatment effect is difficult to lasting prior art deficiency, the invention provides a kind of Chinese medicine composition for the treatment of gout, this Chinese medicine composition good effect, side effect is little, it is mainly made by following raw material: Pseudobulbus cremastrae seu pleiones 10-50 part, Radix Astragali 5-15 gram, Rhizoma Et Radix Notopterygii 10-20 part, Radix Angelicae Sinensis 5-20 part, Radix Rehmanniae 5-10 part, Herba Lysimachiae 5-15 part, Flos Lonicerae 5-15 part, Radix Clematidis 3-10 part, Radix Aconiti Lateralis Preparata 3-8 part, Fructus Lycii 5-15 part, Radix Cyathulae 9-15 part, Rhizoma Pinelliae 3-5 part, Fructus Chaenomelis 5-10 part, Radix Paeoniae Alba 3-5 part, Radix Notoginseng 5-10 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, Semen Ziziphi Spinosae 5-10 part, Poria 5-15 part, Radix Puerariae 3-9 part, Bulbus Allii 5-15 part, Fructus Ligustri Lucidi 6-9 part, Radix Glycyrrhizae 10-15 part.
Pseudobulbus cremastrae seu pleiones is one of conventional Chinese medicine of Chinese Clinical, medicinal have have QI invigorating spleen reinforcing, nourishing; Aid digestion, smart by force, longue meat, antidiarrheal, the effect of eliminating the phlegm.Medicinal history is long, first appeared in < < Sheng Nong's herbal classic > >, lists under Radix Angelicae Pubescentis item.Rhizoma Et Radix Notopterygii bitter in the mouth, pungent, warm in nature.There is loose exterior cold curing rheumatism, the effect in sharp joint.Control affection of exogenous wind-cold, lossless, the anemofrigid-damp arthralgia of having a headache, stiffness of the nape muscular contracture, joint are ached, edema due to wind pathogen edema, the swollen sore of pain etc.Modern analysis shows, Rhizoma Et Radix Notopterygii mainly contains bornene, twists rubber alkene, the compositions such as words product enol and acetic acid Radix Gentianae brain vinegar.Modern pharmacology research Rhizoma Et Radix Notopterygii has significant antipyretic and anti-inflammatory and paroxysmal pain effect.
When being classified as, conventional enrich blood, regulating menstruation, Traditional Chinese medicine used as analgesic, its sweet-bitter flavor, warm in nature, having enriches blood invigorates blood circulation, menstruction regulating and pain relieving, the effect of moisturizing laxation.Modern pharmacology studies show that it all has multiple pharmacological effect for blood system, cardiovascular system.
Herba Lysimachiae, Chinese medicine name.For Ofthe Primulaceae Lysimachia christinae Hance (formal name used at school: dry herb LysimachiachristinaeHance).All there is distribution each province, the south of the River.Summer, Qiu Erji gather.Remove impurity, dry, cutting is raw to be used.There is heat-clearing and toxic substances removing, dissipating blood stasis for subsidence of swelling, the effect of dampness removing jaundice eliminating, can be used for pyretic stranguria, and husky pouring urinated and puckeryly had a pain, jaundice dark coloured urine, carbuncle furuncle, venom, liver and bile stone, the diseases such as lithangiuria.Modern study, these product mainly contain phenolic constituent and sterol, flavonoid, aminoacid, tannin, volatile oil, choline, potassium salt etc.Also have calculus, antibacterial, antiinflammatory action, all has inhibitory action to humoral immunization, cellular immunization.Flos Lonicerae is cold in nature, and sweet in the mouth enters lung, the heart, stomach warp, has the effect of heat-clearing and toxic substances removing, antiinflammatory, tonify deficiency treatment wind, cures mainly disease under distension, epidemic febrile disease heating, the diseases such as pyretic toxicity carbuncle and ulcer and tumor.The diseases such as it is dizzy for giddy, xerostomia is done yearningly, hyperhidrosis is unhappy, enteritis, bacillary dysentery, measles, pneumonia, encephalitis b, epidemic encephalitis, acute mastitis, septicemia, appendicitis, skin infection, carbuncle furuncle, erysipelas, parotitis, suppurative tonsillitis all have certain curative effect.
Radix Clematidis belongs to medicinal plants, medical material Ji Yuan source is more, the contained Radix Clematidis such as < < Kaibao Bencao > >, < < Bencao Tujing > >, < < Herbal for Relief of Famines > > are goatweed; The contained Radix Clematidis of < < the southern regions of the Yunnan Province book on Chinese herbal medicine > >, be feverfew, and current use mostly be the contained cohosh Radix Clematidis of the < < herbal > > of China, Clematis hexapetala etc.Domestic distributed more widely, its root and stem be used as medicine there is rheumatism, effect that the meridian dredging, the bone that disappears are choked.In modern clinic practice, its new purposes is constantly found, as treatment cholelithiasis, calcanean spur, talalgia, the esophageal carcinoma etc.Fructus Lycii (formal name used at school: Lycium chinense) be the multi-branched shrub plant of Solanaceae Lycium, high 0.5-1 rice, can reach more than 2 meters during cultivation.All there is distribution both at home and abroad.Fructus Lycii whole body is precious, and bright Li Shizhen (1518-1593 A.D.) < < Compendium of Materia Medica > > records: " spring is adopted Folium Lycii, name day essence grass; Summer picks flowers, name Sempervivum tectorum; Qiu Caizi, name Fructus Lycii; Dong Caigen, name Cortex Lycii ".Fructus Lycii tender leaf also claims Fructus Lycii head, edible or make Fructus Lycii tea.Modern study, Fructus Lycii has the blood glucose of reduction, lipotropy, and can antiatherogenic effect.
Radix Notoginseng is dry root and the rhizome of panax araliaceae plant Panax notoginseng (Burk.) F.H.Chen.Excavate before the flowers are in blossom autumn, cleans, and separately main root, a root and rhizome, dry.Supporting root is practised and is claimed " rib ", and rhizome is practised title " clip ".Sweet, the micro-hardship of property, temperature.Return liver, stomach warp.Dissipating blood stasis hemostasis, subduing swelling and relieving pain.For spitting of blood, to spit blood, epistaxis, has blood in stool, metrorrhagia, traumatic hemorrhage, breast ventral spine pain, tumbling and swelling.
Radix Cyathulae is the plant that Amaranthaceae Radix Cyathulae belongs to, and its property bitter but sweet flavor acid is flat, has promoting blood circulation to restore menstrual flow, invigorating the liver and kidney, bone and muscle strengthening, inducing diuresis for treating stranguria syndrome, draws the descending effect of blood (fire), be usually used in treating the gynaecopathia such as amenorrhea, dysmenorrhea, menoxenia, puerperal abdonimal pain of stagnation of blood stasis, traumatic injury, the soreness of waist and knee joint of suffering from a deficiency of the kidney, weakness of the lower extremities, hematuria; dysuria, Urethra astringent pain and intimately go up the cards such as headache that inflammation causes, dizzy, haematemesis, epistaxis.
The pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go loose, the up top, mountain peak that reaches; Enter again blood system, the descending sea of blood that reaches.Blood circulation promoting and blood stasis dispelling effect is extensive, the various diseases of suitable stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.It is the gas medicine in blood that former times people calls Rhizoma Chuanxiong, nearly says the functions such as pungent loose, the resolving depression of its residence, sensible, pain relieving.
The Radix Angelicae Dahuricae, warm in nature, acrid in the mouth is micro-sweet, has expelling wind and removing dampness; Logical surreptitiously pain relieving; The effect of detumescence and apocenosis.Main headache due to common cold; Supraorbital bone pain; Toothache; Nasal obstruction; Nasal sinusitis; Domination of damp pathogen chronic diarrhea; Women leucorrhea; Ulcer sores; Venom.Clinical in headache due to common cold, supraorbital bone pain, nasal obstruction, nasal sinusitis, toothache, leucorrhea, skin infection swells and ache.Also can be used for the cold expelling that induces sweat, wind-expelling pain-stopping, clearing the nasal passage, dampness leukorrhagia stopping, detumescence and apocenosis.Control headache, supraorbital bone pain, toothache, nasal sinusitis, cold-damp stomachache, hemorrhoidal hamorrhage anal fistula, leucorrhea with red and white discharge, ulcer sores, skin pruritus due to dryness, scabies.Rhizoma Atractylodis have drying damp and strengthening spleen, expelling wind and cold, and the effect of improving eyesight, for dampness taste, distension and fullness in the abdomen, cold-damp leucorrhea, damp-warm diseases and damp invasion of lower energizer, foot swelling and pain in knee, flaccidity are soft unable.Control dampness taste, and see the thick disease such as turbid of distension and fullness in the abdomen, inappetence, fatigue and weakness, white and greasy fur, the compatibilities such as normal and Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae are applied.
Radix Aconiti Lateralis Preparata is the processed goods of the daughter root of ranunculaceae plant Aconitum carmichjaelii Debx. Aconitum carmichaelii Debx.Late June to early August excavates, and removes parent root, fibrous root and silt, practises and claims " mud Radix Aconiti Lateralis Preparata ".Property sweet, cold.Attach to the lung and stomach meridians.Heat-clearing and toxic substances removing, dispelling wind dredging collateral.For epidemic febrile disease heating, toxic-heat and blood stasis, carbuncle skin infection, rheumatism pyretic arthralgia, redness and swelling of joints burning pain.
Radix Puerariae, is legume pueraria lobata, is a kind of normal food vegetable of some provinces and regions of southern china, its sweet in the mouth is cool good to eat, is often used as Baoshang.Its main component is starch, in addition containing having an appointment 12% flavone compound, comprises that Semen sojae atricolor (Semen Glycines) glycoside, daidzein, puerarin etc. more than 10 plant; And contain daucosterol, aminoacid, Coumarins etc.Can be used as medicinal application.Modern medicine and pharmacology research shows: Radix Puerariae contains abundant puerarin, this glucoside of Xun Gensu, soybean isoflavone, daidzein, ammonia pours the important biomolecule active substances useful to human body such as acid, trace element, triterpene substance alkali.There is nourishing the human Body, beauty care, slow down aging, improve osteoporosis, regulate estrogen level, remove rubbish in body, and improve the plurality of health care functions such as circulation, lowering blood-fat and reducing weight, adjusting blood pressure, to care women's youth, more seem particularly important.
The Radix Paeoniae Alba is the famous traditional parts of generic medicinal plants of China, applicating history is long, and Radix Paeoniae begins to be loaded in the < < of Eastern Han Dynasty Sheng Nong's herbal classic > >, classifies middle product as, note has " main pathogen; Radix Paeoniae Alba stomachache, except arthralgia due to stagnation of blood, broken hard long-pending; cold and heat hernia abdominal mass; pain relieving, diuresis, QI invigorating ".Nourishing blood to suppress the hyperactive liver, slow middle pain relieving, yin fluid astringing is received antiperspirant.Control the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, is with inferior disease.
The Rhizoma Pinelliae (formal name used at school: Pinellia ternata), have another name called ground literary composition, keep field etc., belong to Arales.Be distributed widely in the areas such as Yangtze River in China basin and northeast, North China.Medicinal plants, has drying dampness to eliminate phlegm, and stopping nausea and vomiting by lowering the adverse flow of QI is raw with the furuncle and phyma effect that disappears.Effect has drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass.For abundant expectoration cough with asthma, phlegm retention vertigo and palpitation, dizziness due to wind-phlegm, syncope due to accumulation of phlegm headache, vomiting regurgitation, breast gastral cavity painful abdominal mass is vexed, globus hystericus; Raw with external treatment carbuncle sucutaneous nodule.
Fructus Ligustri Lucidi is the fruit of Oleaceae Ligustrum plant Fructus Ligustri Lucidi.There is tonifying liver kidney yin, the effect of crow palpus improving eyesight.Modern medicine study thinks that the effect that Fructus Ligustri Lucidi can suppress helicobacter pylori can treat gastropathy, also has and suppresses purine abnormal metabolism for the treatment of gout and hyperuricemia.For the hepatic and renal YIN deficiency, soreness of waist tinnitus, early whitening of beard and hair; Unseeing, poor vision; Fever due to yin deficiency, gastropathy and gout and and hyperuricemia.
Chinese medicine composition of the present invention on Chinese medicinal components is selected, take except long-pending numbness, dispersing wind and cold, wind-damp dispelling, bone and muscle strengthening be main standard, after Chinese medicine composition combination of the present invention, there is significant antiinflammatory, analgesia and activating blood circulation to dissipate blood stasis effect.The present invention has carried out preferably the parts by weight of above-mentioned all taste Chinese medicine, and preferred condition is the enhancing of medicine to gout treatment effect after drug matching is used.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by the raw material of following weight portion: 15 parts of Pseudobulbus cremastrae seu pleiones, 12 grams of the Radixs Astragali, 10 parts of Rhizoma Et Radix Notopterygiis, 12 parts of Radix Angelicae Sinensis, 5 parts, the Radix Rehmanniae, 5 parts of Herba Lysimachiaes, 10 parts of Flos Loniceraes, 6 parts of Radix Clematidis, 6 parts of Radix Aconiti Lateralis Preparatas, 15 parts of Fructus Lyciis, 9 parts of Radix Cyathulaes, 5 parts of the Rhizoma Pinelliaes, 5 parts of Fructus Chaenomeliss, 5 parts of the Radix Paeoniae Albas, 5 parts of Radix Notoginseng, 9 parts of Rhizoma Chuanxiongs, 10 parts of the Radixs Angelicae Dahuricae, 5 parts of Semen Ziziphi Spinosaes, 12 parts, Poria, 6 parts of Radix Puerariaes, 7 parts, Bulbus Allii, 6 parts of Fructus Ligustri Lucidi, 12 parts, Radix Glycyrrhizae.
Preferably, Chinese medicine composition of the present invention also further contains Radix Aucklandiae 3-7 part, Radix Et Rhizoma Rhei 3-5 part, Radix Polygalae 5-9 part.Preferably, Chinese medicine composition of the present invention also further contains 7 parts of the Radix Aucklandiae, 5 parts of Radix Et Rhizoma Rhei, 9 parts of Radix Polygalaes.Radix Aucklandiae acrid in the mouth, hardship, warm in nature; Return spleen, stomach, liver, large intestine channel, fragrance row is loose, can rise and can fall.It has following effect: promoting the circulation of QI to relieve pain, for abdominal distention, lack of appetite due to stagnation of QI in spleen and stomach, vomit; Regulate the flow of vital energy soothing the liver, hypochondriac pain 3. spleen invigorating that cause for QI stagnation of the liver and galibladder disappear stagnant, the stagnant gas of adjustable gastrointestinal.Treatment stomachache, diarrhoea, tenesmus.Radix Et Rhizoma Rhei is being collectively referred to as of perennial plant of multiple Polygonaceae Rheum, is also the title of Chinese crude drug.In the document of CHINESE REGION, the todaiwo,rhizoma often that " Radix Et Rhizoma Rhei " refers to.In China, Radix Et Rhizoma Rhei is mainly done medicinal, but in Europe and the Middle East, their Radix Et Rhizoma Rhei often refers to the Rheum kind that other several work is edible, and stem is red.Gas delicate fragrance, bitter in the mouth is and micro-puckery, and that chews sticks to one's teeth, and has sand feeling.Autumn Mo in the withered or inferior spring of stem and leaf excavates before germinateing.Remove radicula, scrape off crust, valve cutting or section, rope is worn bunchiness and is dried or convection drying.Chinese herb rhubarb has attacks the effects such as stagnant, clearing away damp-heat, pathogenic fire purging, removing heat from blood, blood stasis dispelling, removing toxic substances.Radix Polygalae is conventional Chinese medicine, be recorded in the earliest < < Sheng Nong's herbal classic > >, classify as top gradely, and be regarded as supporting life key medicine, warm in nature, bitter in the mouth, pungent, the function of there is the Fructus Alpiniae Oxyphyllae of calming the nerves, eliminate the phlegm, subsiding a swelling, the insomnia and dreamful sleep causing for disarmony between the heart and kidney, forgetful palpitation with fear, staring spells, expectoration is not well, sore swollen toxin, breast swell and pain.
In order to express better Chinese medicine composition of the present invention, Chinese medicine composition of the present invention can be prepared into conventional clinically dosage form.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule.Preferably, Chinese medicine composition of the present invention is prepared into powder, water preparation, tablet or capsule according to conventional preparation technology.
The present invention also provides a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into powder, according to the 3-10 of powder gross weight, doubly adding volumetric concentration is the alcoholic solution of 40%-95%, reflux, extract, three times, each return time is 1-5h, filter, filtrate recycling ethanol, obtains Chinese medical concrete after being dried; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
Content involved in the present invention, that be not particularly limited is prior art, and those skilled in the art can be according to concrete performance flexible realization in addition.
The present invention also asks for protection the purposes of above-mentioned Chinese medicine composition in preparation treatment gout medicine.Can warming the meridian for promoting the flow of YANG QI by taking medicine of the present invention, diaphoresis expelling pathogenic factors from muscles, table gas and, warm extremity, induce sweat the exogenous cold of faling apart, and remove limb aching pain, can relieve the pain again to take into account and get through passages through which vital energy circulates, disintegrate inner cold-evil, the YIN pathogen of dispelling, metancenter will, making the adverse-rising QI downwards, make healthy energy playback, bad odor sedimentation, dissolve, dislike thing and just discharge from perspiration or two.Make the vital organs of the human body in order, can fundamentally treat gout, and treatment cycle is short, cost is low, and toxic and side effects is little, and therapeutic effect is desirable.Pharmaceutical composition of the present invention, when treatment gout, demonstrates significant anti-inflammatory and antalgic, detumescence and reduces blood uric acid active.Drug effect embodiment 19 of the present invention shows, mice licks foot response latency time showing, with model group comparison, after administration after 1h and 2h, all be greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate that this Chinese medicine composition of the present invention can extend adding the sufficient response latency that mice stimulates hot plate, has certain analgesic activity.Under same experiment condition, the other purine group of positive control drug (1h,
p< 0.05; 2h,
p< 0.01) also significant prolongation mice incubation period of adding foot reaction, have certain analgesic activity.Embodiment 20 Chinese medicine composition of the present invention confirms the result of the impact of the inhibitory action of Gout Model rat arthroncus and blood uric acid, each group of Chinese medicine composition of the present invention and positive controls and model group comparison, all can obviously suppress rat due to uric acid sodium ankle swelling (
p< 0.01), wherein in Chinese medicine composition of the present invention, high dose joint diameter of 5h and 80h after modeling after modeling is compared the difference with utmost point significance with model group.Result confirms, Chinese medicine composition of the present invention compare with model group obvious reduction hyperuricemia rat serum uric acid level (
p< 0.01), wherein in Chinese medicine composition of the present invention, high dose group is compared the difference with utmost point significance with model group.Drug effect embodiment of the present invention 21 shows, with model group comparison, the low middle Senior Three of a Chinese medicine composition of the present invention dosage group all can significantly reduce dimethylbenzene induced mice ear swelling value (
p< 0.01), show that Chinese medicine composition of the present invention has the effect of the mice ear of remarkable inhibition dimethylbenzene induction, and there is significant dose-effect relationship in its reduction effect to ear swelling.Under same experiment condition, the other purine group of positive control drug also significantly reduce ear swelling value (
p< 0.05), but its antiphlogistic effects is obviously not as good as Chinese medicine composition of the present invention.
In a word, pharmaceutical composition of the present invention, aspect treatment gout, compared with prior art has following advantage:
1) compare with the other purine of positive control drug, pharmaceutical composition Chinese medicine composition of the present invention is not only more remarkable at antiinflammatory and ease pain, and aspect activating blood circulation to dissipate blood stasis, be also significantly better than positive drug, this shows that the present composition has significant synergism in gout treatment, not only can significantly improve the symptom of gout, can also delay the development of gout, contribute to the recovery from illness process of patient with gout.
2) compare with the chemotherapeutic agent of current treatment gout, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, particularly it does not produce any destruction for intestinal mucosa, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, has significantly improved the compliance of patient with gout, and has improved patient's quality of life.
3) existing antibiotic medicine gout initial stage therapeutic effect still can, but along with obvious drug resistance problem all appears in the prolongation for the treatment of time, its therapeutic effect for gout declines.In Chinese medicine composition of the present invention, contain multi-medicament component, action target spot is numerous, has effectively solved the Commpensation And Adaptation of gout treatment medicine, its to the therapeutic effect of gout not because treatment time extends and to decline.
4) compare with Chinese medicine preparation of the prior art, Chinese medicine composition raw material of the present invention is more easy to get, and treatment gout effect is more excellent.
The specific embodiment
By specific embodiment, further describe the present invention below, the present invention is not limited only to following examples.Within the scope of the invention or within not departing from content of the present invention, spirit and scope, the change that the present invention is carried out, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
First's Chinese medicinal composition preparation of the present invention, preparation and using method thereof
Embodiment 1-6 Chinese medicine composition composition powders
Table 1 Chinese medicine composition composition powders prescription of the present invention
Embodiment 1 preparation method: get each medical material in compositions, grind to form powdery according to common process, cross 100 mesh sieves, little fire drying is standby, obtains powder.During use, with directly taking after mixing it with water after water dissolution.Embodiment 2-6 preparation method is with embodiment 1.
Embodiment 7-12 Chinese medicine composition water preparation
Table 2 Chinese medicine composition water preparation prescription of the present invention
Embodiment 7 preparation methoies: get each medical material in prescription, according to conventional decocting for Chinese herbal medicine technological operation, filtering medicinal residues and get final product.This water preparation (or claim decoction) is during for gout treatment, and take 2-3 every day.Embodiment 8-12 preparation method and using method are with embodiment 7.
Embodiment 13-18 Chinese medicine composition tablet/capsule of the present invention
Table 3 Chinese medicine composition tablet of the present invention/capsule prescription
Embodiment 13 preparation technologies: each traditional Chinese medicine powder of getting recipe quantity is broken into coarse powder, according to 5 times of coarse powder gross weight, adding volumetric concentration is 80% alcoholic solution, reflux, extract, three times, the each 3h of return time, filters filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Chinese medical concrete drying, pulverizing are made to dried cream powder, add conventional adjunct ingredient to utilize prior art to be prepared into tablet or capsule.
Embodiment 14-18 preparation technology is with embodiment 13.
Second portion Chinese medicine composition pharmacodynamic study of the present invention
The impact of embodiment 19 Chinese medicine composition of the present invention on mice hot-plate analgesia
1) mice hot plate pain model is made
Body weight 20g left and right female mice is placed on hot plate dolorimeter, (licking metapedes time <5s or >30s throws aside to screen 90 of qualified female mices, for preventing foot, scald, also should establish deadline, be generally 60s), be the threshold of pain index incubation period that the mice of take is added metapedes reaction, get 60 jennies, be divided into 5 groups, 12/group, i.e. model group, other purine group, Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 3) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, dosage is as shown in table 10, after successive administration 14d, and the time that after mensuration last medicine, 60min, 120min add foot reaction.
2) Chinese medicine composition of the present invention is on licking the impact of foot response latency in the experiment of mice hot-plate analgesia
Mice licks foot response latency time showing, with model group comparison, after administration after 1h and 2h, be all greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate that this Chinese medicine composition of the present invention can extend adding the sufficient response latency that mice stimulates hot plate, has certain analgesic activity.Under same experiment condition, the other purine group of positive control drug (1h,
p< 0.05; 2h,
p< 0.01) also significant prolongation mice incubation period of adding foot reaction, have certain analgesic activity.The results are shown in Table 4.
Table 4 mice lick foot response latency timetable (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
Embodiment 20 Chinese medicine composition of the present invention is on the inhibitory action of Gout Model rat arthroncus and the impact of blood uric acid
1) animal model and administration
Get body weight and be 60 of the male rats of 200 ~ 220g, after adapting to laboratory 5d, weigh, number, be divided at random 6 groups, every group 10, i.e. Normal group, model group, positive drug group (allopurinol), Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 3) high dose group, middle dosage group, low dose group.Chinese medicine composition of the present invention senior middle school low dose group group rat is pressed respectively 1.8g/kg, 0.6g/kg, 0.1g/kg gastric infusion, the distilled water of the capacity such as Normal group and model group gavage, administration every day 1 time, continuously gavage 5d.
Prepare the crystallization of uric acid sodium: 194ml distilled water adds 6mlNaOH simultaneously, boil and add 1g uric acid, with dilute hydrochloric acid, adjust pH7.2, stir coolingly, 4 ℃ of Refrigerator store 24h, remove supernatant, with filter paper, precipitate moisture is blotted, put into 70 ℃, drying baker and dry 2h, take out, scrape powder, put into mortar pulverization, wire-mesh screen with aperture 250mm, sieves, and bottles standby.Used time gets the crystallization of 250mg uric acid sodium and adds 45ml0.9% chloride injection solution, then adds 5ml Tween 80, and heated and stirred, is made into 50ml uric acid sodium solution.
Except normal group, it is point of puncture that every experimental mouse is all selected the outer proceeds posterolateral of right ankle joint, and pin mouth inclined-plane becomes 45 angles to penetrate ankle joint chamber with tibia towards front upper place, with No. 4 syringe needles, to articular cavity, injects 0.2ml uric acid sodium solution, the joint capsule offside of take is heaved as injection standard, induction Gout Model.Each organizes rat 3h before modeling, after modeling, and after medication 5d (being 120h after modeling) respectively in tested ankle joint same area, with its diameter of vernier caliper measurement, after observing modeling front and back and medication treatment, respectively organize the diameter variation of tested joint, after last administration, 2h puts to death rat, abdominal aortic blood, 2500r/min, centrifugal 5min, gets determination of serum uric acid level, carries out group difference comparison.
2) experimental result
Chinese medicine composition of the present invention affects table 5 result proved invention each group of Chinese medicine composition and positive controls and model group comparison to the inhibitory action of Gout Model rat arthroncus and blood uric acid, the ankle swelling (P<0.01) that all can obviously suppress rat due to uric acid sodium, wherein in Chinese medicine composition of the present invention, high dose joint diameter of 5h and 80h after modeling after modeling is compared the difference with utmost point significance with model group.Table 6 result confirms, Chinese medicine composition of the present invention is compared the serum uric acid level (P<0.01) of obvious reduction hyperuricemia rat with model group, wherein in Chinese medicine composition of the present invention, high dose group is compared the difference with utmost point significance with model group.
The inhibitory action of table 5 Chinese medicine composition of the present invention to rat arthroncus
Compare with Normal group, * * P < 0.01, compares with model group, #P < 0.05, ##P < 0.01.
The impact of table 6 Chinese medicine composition of the present invention on Gout Model Rats blood uric acid due to uric acid sodium
Compare with Normal group, * * P < 0.01, compares with model group, #P < 0.05, ##P < 0.01.
Embodiment 21 Chinese medicine composition xylol of the present invention causes the impact of mice ear
Get 60 of healthy ICR mices, male and female half and half, minutes 6 groups, 10/group, i.e. model group, other purine group (Haikou Kangliyuan Pharmaceutical Co., Ltd), Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 3) low dose group, middle dosage group and high dose group.1 time/d of every ig administration; Administration 14d, 60min after last medicine, mouse right ear is evenly smeared dimethylbenzene 0.03mL/ and is only caused swollenly, cuts ears and beat auricle and weigh after 2h, calculates ear swelling value (mg).Swelling value=auris dextra weight-left ear weight.
Result shows (in Table 7), with model group comparison, the low middle Senior Three of a Chinese medicine composition of the present invention dosage group all can significantly reduce dimethylbenzene induced mice ear swelling value (
p< 0.01), show that Chinese medicine composition of the present invention has the effect of the mice ear of remarkable inhibition dimethylbenzene induction, and there is significant dose-effect relationship in its reduction effect to ear swelling.Under same experiment condition, the other purine group of positive control drug also significantly reduce ear swelling value (
p< 0.05), but its antiphlogistic effects is obviously not as good as Chinese medicine composition of the present invention.
The impact of table 7 Chinese medicine composition xylol of the present invention induced mice ear swelling (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
Claims (7)
1. a Chinese medicine composition for the treatment of gout, it is characterized in that the raw material that described Chinese medicine composition comprises following weight portion: Pseudobulbus cremastrae seu pleiones 10-50 part, Radix Astragali 5-15 gram, Rhizoma Et Radix Notopterygii 10-20 part, Radix Angelicae Sinensis 5-20 part, Radix Rehmanniae 5-10 part, Herba Lysimachiae 5-15 part, Flos Lonicerae 5-15 part, Radix Clematidis 3-10 part, Radix Aconiti Lateralis Preparata 3-8 part, Fructus Lycii 5-15 part, Radix Cyathulae 9-15 part, Rhizoma Pinelliae 3-5 part, Fructus Chaenomelis 5-10 part, Radix Paeoniae Alba 3-5 part, Radix Notoginseng 5-10 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, Semen Ziziphi Spinosae 5-10 part, Poria 5-15 part, Radix Puerariae 3-9 part, Bulbus Allii 5-15 part, Fructus Ligustri Lucidi 6-9 part, Radix Glycyrrhizae 10-15 part.
2. the Chinese medicine composition for the treatment of gout as claimed in claim 1, is characterized in that being made by the raw material of following weight portion: 15 parts of Pseudobulbus cremastrae seu pleiones, 12 grams of the Radixs Astragali, 10 parts of Rhizoma Et Radix Notopterygiis, 12 parts of Radix Angelicae Sinensis, 5 parts, the Radix Rehmanniae, 5 parts of Herba Lysimachiaes, 10 parts of Flos Loniceraes, 6 parts of Radix Clematidis, 6 parts of Radix Aconiti Lateralis Preparatas, 15 parts of Fructus Lyciis, 9 parts of Radix Cyathulaes, 5 parts of the Rhizoma Pinelliaes, 5 parts of Fructus Chaenomeliss, 5 parts of the Radix Paeoniae Albas, 5 parts of Radix Notoginseng, 9 parts of Rhizoma Chuanxiongs, 10 parts of the Radixs Angelicae Dahuricae, 5 parts of Semen Ziziphi Spinosaes, 12 parts, Poria, 6 parts of Radix Puerariaes, 7 parts, Bulbus Allii, 6 parts of Fructus Ligustri Lucidi, 12 parts, Radix Glycyrrhizae.
3. the Chinese medicine composition for the treatment of gout as claimed in claim 1, is characterized in that described Chinese medicine composition also contains the raw material of following weight portion: Radix Aucklandiae 3-7 part, Radix Et Rhizoma Rhei 3-5 part and Radix Polygalae 5-9 part.
4. the Chinese medicine composition for the treatment of gout as claimed in claim 3, is characterized in that described Chinese medicine composition also contains the raw material of following weight portion: 7 parts of the Radix Aucklandiae, 9 parts of 5 parts of Radix Et Rhizoma Rhei and Radix Polygalaes.
5. the Chinese medicine composition of the treatment gout as described in as arbitrary in claim 1-4, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
6. the preparation method of the Chinese medicine composition of a treatment gout as claimed in claim 5, it is characterized in that comprising the following steps: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, according to the 3-10 of coarse powder gross weight, doubly adding volumetric concentration is the alcoholic solution of 40%-95%, reflux, extract, three times, each return time is 1-5h, filter, filtrate recycling ethanol, obtains Chinese medical concrete after being dried.
7. the Chinese medicine composition of the treatment gout as described in as arbitrary in claim 1-4 is purposes in preparation treatment gout medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410327286.4A CN104042925A (en) | 2014-07-10 | 2014-07-10 | Traditional Chinese medicinal composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410327286.4A CN104042925A (en) | 2014-07-10 | 2014-07-10 | Traditional Chinese medicinal composition for treating gout and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104042925A true CN104042925A (en) | 2014-09-17 |
Family
ID=51496648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410327286.4A Pending CN104042925A (en) | 2014-07-10 | 2014-07-10 | Traditional Chinese medicinal composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042925A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383363A (en) * | 2014-11-28 | 2015-03-04 | 陈敦华 | Traditional Chinese medicinal composition for treating gout |
| CN104800637A (en) * | 2015-04-27 | 2015-07-29 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating hyperuricemia with joint swelling |
| CN106511498A (en) * | 2016-12-21 | 2017-03-22 | 四川何天祺医院管理有限公司 | Pharmaceutical composition for treating gout and bone diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520497A (en) * | 2013-10-20 | 2014-01-22 | 杨献华 | Chinese medicinal composition for treating gout and preparation method thereof |
-
2014
- 2014-07-10 CN CN201410327286.4A patent/CN104042925A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520497A (en) * | 2013-10-20 | 2014-01-22 | 杨献华 | Chinese medicinal composition for treating gout and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 唐丽: "痛风的中医临床及实验研究近况", 《中国中医急症》 * |
| 郜顺兴等: "中药治疗痛风性关节炎的计量分析", 《河南中医》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383363A (en) * | 2014-11-28 | 2015-03-04 | 陈敦华 | Traditional Chinese medicinal composition for treating gout |
| CN104383363B (en) * | 2014-11-28 | 2018-06-19 | 陈敦华 | Treat the Chinese medicine composition of gout |
| CN104800637A (en) * | 2015-04-27 | 2015-07-29 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating hyperuricemia with joint swelling |
| CN106511498A (en) * | 2016-12-21 | 2017-03-22 | 四川何天祺医院管理有限公司 | Pharmaceutical composition for treating gout and bone diseases |
| CN106511498B (en) * | 2016-12-21 | 2020-02-14 | 四川何天祺医院管理有限公司 | Pharmaceutical composition for treating gout and bone diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103736036A (en) | Drug for treating nonalcoholic fatty liver disease and preparation method thereof | |
| CN105497816A (en) | Traditional Chinese medicine preparation for treating atherosclerosis and preparation method thereof | |
| CN104042925A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN102293964B (en) | Medicine for treating gastric ulcer, and preparation method thereof | |
| CN105435197A (en) | Pharmaceutical composition for treating chronic lymphocytic thyroiditis and preparation method thereof | |
| CN104523873A (en) | Pharmaceutical composition for treating gout | |
| CN104906507A (en) | Traditional Chinese medicine combination for lowering blood pressure and toning physical fitness | |
| CN104398927A (en) | Traditional Chinese medicinal preparation for treating gonarthromeningitis | |
| CN104042981A (en) | Medicament for treating postnatal constipation and preparation method thereof | |
| CN103041320B (en) | Traditional Chinese medicine composition for treating cervical spondylosis and preparation method thereof | |
| CN105055931A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease | |
| CN105535864A (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating acute or chronic rhinitis | |
| CN104547953A (en) | Traditional Chinese medicine composition for treating arthritis and preparation method thereof | |
| CN114712470B (en) | Medicine for treating deficiency of kidney of men and preparation method thereof | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same | |
| CN103690869A (en) | Traditional Chinese medicine for treating irritable bowel syndrome and preparation method thereof | |
| CN106344838A (en) | Chinese medicinal composition for treating oral ulcer | |
| CN106266427A (en) | A kind of Traditional Chinese medicinal liquor treating nephropathy and preparation method thereof | |
| CN103656199A (en) | Traditional Chinese medicine for treating cough caused by kidney Yin deficiency | |
| CN105125860A (en) | Preparation for effectively treating osteoporosis | |
| CN103877344A (en) | Sea cucumber containing traditional Chinese medicinal preparation for treating epilepsy | |
| CN104383361A (en) | Traditional Chinese medicine preparation for treating acute infectious hepatitis | |
| CN104758841A (en) | Traditional Chinese medicine preparation for treating appendicitis and preparation method of traditional Chinese medicine preparation | |
| CN105106405A (en) | Traditional Chinese medicine for treating allergic eczema | |
| CN105031335A (en) | Medicament for nursing and treatment after microwave pulverization of gastric bezoars and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140917 |